Overall rank by patents
#26,123
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
DRUG Plastics & Glass Company, Inc.
USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, active 2015–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: B65D (CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR F).
10
Total patents granted
4
CPC technology areas
11.1
Avg claims per patent
-33%
5-year filing velocity
The verdict
DRUG holds 10 US patents across 4 technology areas, rank #26,123 of 50,000 tracked assignees.
- #26,123
- of 50,000 US assignees by volume
- Top 86%
- by Innovation Score (24.2/100)
- 11.1
- avg claims per patent
- -33%
- filing velocity, last 5 yrs
Portfolio overview
DRUG Plastics & Glass Company, Inc. has been granted 10 US utility patents between 2015 and 2024, placing DRUG Plastics & Glass Company, Inc. at rank #26,123 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.1 claims per patent with primary concentration in B65D (CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR F). As a US Corporation, DRUG Plastics & Glass Company, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, DRUG sits between Dromont S.p.a. (10 patents, rank #26,119) and Dukosi Limited (10 patents, rank #26,127) - the closest US assignees by grant volume. The composite Innovation Score of 24.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 6 in the 2015–2019 window, a -33% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. DRUG Plastics & Glass Company, Inc.'s 11.1 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark DRUG Plastics & Glass Company, Inc. against peers pursuing similar technology classes.
Who files at DRUG's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Dromont S p A
DROMONT S.p.A.
10 patents
- Dropworks
DROPWORKS, INC.
10 patents
- DRS Power & Contr…
DRS Power & Control Technologies, Inc.
10 patents
- DRS Sustainment S…
DRS Sustainment Systems, Inc.
10 patents
- Drvision
DRVISION TECHNOLOGIES LLC
10 patents
- DS Smith Plastics
DS Smith Plastics, Ltd.
10 patents
- DST Innovations
DST INNOVATIONS, LTD.
10 patents
- Dukosi
DUKOSI LIMITED
10 patents
- DRUG Plastics & G… ◀
DRUG PLASTICS & GLASS COMPANY, INC.
10 patents
What this shows DRUG holds 10 patents at rank #26,123, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
DRUG's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
24 Top 86% higher than 14% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 10.0% |
| 2018 | 1 | 10.0% |
| 2019 | 4 | 40.0% |
| 2020 | 1 | 10.0% |
| 2021 | 1 | 10.0% |
| 2023 | 1 | 10.0% |
| 2024 | 1 | 10.0% |
Which technologies does DRUG Plastics & Glass Company, Inc. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Simple
Velocity Declining
Frequently Asked Questions
How many patents does DRUG Plastics & Glass Company, Inc. hold?
DRUG Plastics & Glass Company, Inc. holds 10 US granted patents filed between 2015 and 2024, spanning 4 technology areas.
What is DRUG Plastics & Glass Company, Inc.'s Innovation Score?
DRUG Plastics & Glass Company, Inc. has an Innovation Score of 24.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does DRUG Plastics & Glass Company, Inc. focus on?
DRUG Plastics & Glass Company, Inc.'s top technology area is B65D (CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES) with 7 patents. The company has filed patents in 4 CPC subclasses total.
Is DRUG Plastics & Glass Company, Inc.'s patent filing rate increasing or decreasing?
DRUG Plastics & Glass Company, Inc.'s recent filing velocity is -33% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for DRUG Plastics & Glass Company, Inc.'s patents?
DRUG Plastics & Glass Company, Inc.'s patents average 11.1 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the DRUG Plastics & Glass Company, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
DRUG's 10 grants land it in the top 86% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - DRUG ranks #26,123 of 50,000. Top 50 holders
- Most of this portfolio concentrates in B65D - see who else leads that technology area. B65D leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.